Elucidating the mechanism of regulation of transforming growth factor β type II receptor expression in human lung cancer cell lines
- Sunil K. Halder,
- Yong Jig Cho,
- Arunima Datta,
- Govindaraj Anumanthan,
- Amy Joan L. Ham,
- David P. Carbone
- Vanderbilt University,
- VA Medical Center
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Lung carcinogenesis in humans involves an accumulation of genetic and epigenetic changes that lead to alterations in normal lung epithelium, to in situ carcinoma, and finally to invasive and metastatic cancers. The loss of transforming growth factor β (TGF-β)-induced tumor suppressor function in tumors plays a pivotal role in this process, and our previous studies have shown that resistance to TGF-β in lung cancers occurs mostly through the loss of TGF-β type II receptor expression (TβRII). However, little is known about the mechanism of down-regulation of TβRII and how histone deacetylase (HDAC) inhibitors (HDIs) can restore TGF-β-induced tumor suppressor function. Here we show that HDIs restore TβRII expression and that DNA hypermethylation has no effect on TβRII promoter activity in lung cancer cell lines. TGF-β-induced tumor suppressor function is restored by HDIs in lung cancer cell lines that lack TβRII expression. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by either activated Ras or epidermal growth factor signaling is involved in the down-regulation of TβRII through histone deacetylation. We have immunoprecipitated the protein complexes by biotinylated oligonucleotides corresponding to the HDI-responsive element in the TβRII promoter (-127/-75) and identified the proteins/factors using proteomics studies. The transcriptional repressor Meis1/2 is involved in repressing the TβRII promoter activity, possibly through its recruitment by Sp1 and NF-YA to the promoter. These results suggest a mechanism for the downregulation of TβRII in lung cancer and that TGF-β tumor suppressor functions may be restored by HDIs in lung cancer patients with the loss of TβRII expression.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 912-922 (11 pages)Journal (Volume, Issue Number)
Neoplasia (Volume 13, Issue 10)Publication milestones
- Published - 10/2011
Publication status
Published - 10/2011
ISSN
1522-8002Publication IDs
- Scopus: 80054829319
- PubMed: 22028617
Publication metrics
Metrics
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
SciVal
FWCI
1.04
SciVal
Author count
7
SciVal
citations
27
SciVal
Paper percentile
83
PlumX, opens in new tab
Captures
30
Citation count
34
Funding Details
Address all correspondence to: Pran K. Datta, PhD, Department of Surgery, Vanderbilt University School of Medicine, 1161 21st Ave S, A-3310C, MCN, Nashville, TN 37232. E-mail: [email protected] 1This study was supported by R01 CA95195 and CA113519, National Cancer Institute SPORE grant in lung cancer (5P50CA90949, project no. 4), and Veterans Affairs Merit Review Award (to P.K.D.). The authors thank Dr Takashi Takahashi (Aichi Cancer Center Research Institute, Nagoya, Japan), Dr R. Daniel Beauchamp (Vanderbilt University Medical Center), and Dr Jonathan Yingling (Eli Lilly, Indianapolis, IN) for providing plasmids and reagents. The authors do not have any conflict of interests. 2This article refers to supplementary materials, which are designated by Figures W1 to W3 and are available online at www.neoplasia.com. Received 22 April 2011; Revised 5 August 2011; Accepted 8 August 2011 Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00 DOI 10.1593/neo.11576
FundersFunding number
NCI
5P50CA90949
VA
-